Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Platinum-based antineoplastic
Introduction
Overview
Overview
Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents to treat cancer. They are coordination complexes of platinum.
The main dose-limiting side effect of cancer treatment with platinum compounds is neurotoxicity, which causes peripheral neuropathies including polyneuropathy.[1]
Mechanism of action
Mechanism of action
As studied mainly on cisplatin, but presumably for other members as well, platinum-based antineoplastic agents cause crosslinking of DNA as monoadduct, interstrand crosslinks, intrastrand crosslinks or DNA protein crosslinks. Mostly they act on the adjacent N-7 position of guanine, forming 1, 2 intrastrand crosslink.[2][3]
The resultant crosslinking inhibit DNA repair and/or DNA synthesis in cancer cells.
Platinum-based antineoplastic agents are sometimes described as “alkylating-like” due to similar effects as alkylating antineoplastic agents, although they do not have an alkyl group.[4]
Examples
Examples
- cisplatin, the first to be developed.[5] Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%.[6]
- carboplatin, a second-generation platinum-based antineoplastic agent[5]
- oxaliplatin[5]
- satraplatin[5]
- picoplatin[5]
- Nedaplatin
- Triplatin
- Lipoplatin, a liposomal version of cisplatin
References
References
- ↑ PMID 15072449 (PMID 15072449)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ Poklar N, Pilch DS, Lippard SJ, Redding EA, Dunham SU, Breslauer KJ (July 1996). “Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex”. Proc. Natl. Acad. Sci. U.S.A. 93 (15): 7606–11. doi:10.1073/pnas.93.15.7606. PMC 38793. PMID 8755522.
- ↑ Rudd GN, Hartley JA, Souhami RL (1995). “Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals”. Cancer Chemother. Pharmacol. 35 (4): 323–6. doi:10.1007/BF00689452. PMID 7828275.
- ↑ Cruet-Hennequart S, Glynn MT, Murillo LS, Coyne S, Carty MP (April 2008). “Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin”. DNA Repair (Amst.). 7 (4): 582–96. doi:10.1016/j.dnarep.2007.12.012. PMID 18289945.
- ↑ 5.0 5.1 5.2 5.3 5.4 Template:Cite doi
- ↑ Einhorn LH. (1 November 1990). “Treatment of testicular cancer: a new and improved model”. J. Clin. Oncol. 8 (11): 1777–81. PMID 1700077.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]